| DESCRIPTION |
Extended-Spectrum Beta-Lactamases (ESBLs) are enzymes that mediate
Standards Institute (CLSI) testing schema should be used. If an isolate is
confirmed as an ESBL-producer by the CLSI-recommended phenotypic
confirmatory test procedure, then all penicillins, cephalosporins and
aztreonams should be reported as resistant. Cephamycins should be reported
according to their routine test results.
NOTE: Adding Extended-Spectrum Beta Lactamase to the MDRO Tools Lab
Parameter Setup is optional. The purpose of adding pathogens containing
this form of antimicrobial resistance to the parameter set-up is to
identify a patient's current or prior history of ESBL based on laboratory
resistance to extended-spectrum (third generation) cephalosporins (e.g.,
reporting and the time frames that are entered to search for the patient's
status. This information can optionally be displayed on the Isolation
Report. If you would like to incorporate ESBL into the Isolation report,
the result must occur as a retrievable result as a "bacterial etiology" or
in the "BACT RPT REMARK" field. It is appropriate to used Canned Comments
versus Free Text to retrieve results. If free-text is used, it is likely
the report will not display accurate information. Any results contained in
the "Comments" section will not allow incorporation of ESBL into the MDRO
Program Tools software Isolation Report format.
ceftazidime, cefotaxime, and ceftriaxone) and monobactams (e.g, aztreonam)
but do not affect cephamycins (e.g., cefoxitin and cefotetan) or
carbapenems (e.g., imipenem or meropenem).
ESBLs can be difficult to detect because they have different levels of
activity against various cephalosporins. It is critical to test the
appropriate antimicrobial agent. An appropriate Committee on Laboratory
|
